TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · major macro event coming up
RARE

Ultragenyx

Healthcare · Biotechnology

14.50$ -1.8% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Ratios

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Last 12 Full history
Download as CSV

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios RARE
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
Valuation
21,908.1 21,557.2 21,329.8 22,670.2 11,151.4 766.3 188.3 146.9 102.0 42.8 62.6 51.9 29.3 23.8 21.1 30.0 23.2 33.0 22.9 17.9 17.0 16.4 15.2 12.5 8.4 8.9 7.4 8.1 6.2 8.9 8.9 7.4 10.2 7.2 5.9 5.9 4.8 3.4 3.2 4.7
6.2 6.0 5.8 6.1 6.2 5.2 3.5 5.4 5.8 3.6 4.2 4.5 3.4 3.8 4.2 6.9 7.5 7.8 7.2 6.6 6.6 6.3 6.3 6.2 6.2 9.2 12.8 25.3 80.7 14.1 28.1 8.2 15.3 15.8 24.2 23.7 327.9 – – –
20,796.5 20,345.7 20,130.5 21,887.8 10,853.8 727.8 171.3 142.6 99.8 – 58.5 50.2 27.9 19.7 18.7 27.9 22.3 30.4 21.8 17.2 16.5 15.6 14.8 12.0 7.3 8.6 7.2 7.9 6.1 8.5 8.7 6.4 9.9 6.9 5.7 5.6 4.5 2.9 3.0 4.7
-5.9% -6.0% -6.6% -7.3% -9.8% -12.8% -11.4% -8.2% -8.3% -13.4% -8.2% -8.8% -13.9% -15.0% -14.8% -4.2% -3.6% -2.0% -3.2% -6.4% -6.9% -7.1% -8.2% -10.5% -16.5% -16.2% -18.7% -16.9% -21.6% -13.5% -13.8% -13.8% -8.3% -10.8% -11.8% -11.9% -15.0% -20.5% -23.1% -14.4%
Margins
-161,446.9% -107,260.2% -145,808.3% -180,212.1% -108,699.5% -6,412.9% -796.0% -133.0% 98.3% 97.8% 97.7% 97.2% 94.8% 91.3% 95.9% 96.2% 97.3% 97.7% 95.6% 95.5% 95.0% 95.4% 94.9% 93.4% 92.3% 92.2% 91.0% 91.0% 90.6% 89.6% 88.6% 87.1% 86.2% 86.3% 85.1% 85.3% 84.7% 83.8% 83.6% 83.1%
-182,512.5% -186,471.4% -198,751.1% -245,454.3% -149,092.1% -12,593.5% -2,675.0% -1,426.0% -1,003.7% -721.2% -634.2% -556.8% -497.8% -409.0% -365.7% -248.5% -152.7% -121.8% -94.6% -93.4% -104.4% -108.6% -124.1% -140.8% -176.4% -178.6% -173.6% -167.0% -144.5% -131.1% -131.1% -114.0% -102.5% -95.7% -86.9% -82.8% -86.3% -79.6% -83.9% -73.8%
-179,536.7% -184,867.7% -196,546.6% -239,116.4% -143,692.1% -11,567.3% -1,532.1% -703.3% -508.7% -383.7% -550.3% -527.5% -470.2% -388.3% -348.8% -188.5% -119.2% -68.8% -61.0% -97.8% -98.9% -129.2% -141.7% -151.3% -197.5% -194.7% -187.3% -178.9% -154.9% -139.7% -138.6% -121.6% -106.9% -101.6% -93.0% -87.3% -91.9% -85.5% -91.0% -81.8%
-129,050.0% -128,694.0% -140,211.3% -164,637.9% -109,487.7% -9,825.3% -2,143.9% -1,200.6% -850.8% -572.2% -514.5% -455.4% -407.3% -357.0% -312.4% -127.4% -82.5% -65.0% -72.6% -114.5% -117.8% -117.2% -125.2% -131.2% -139.7% -144.9% -137.7% -137.3% -134.9% -120.1% -122.8% -102.3% -84.1% -77.5% -69.9% -70.0% -71.6% -70.2% -72.8% -68.3%
Returns
-50.4% -51.9% -53.5% -64.6% -79.8% -78.8% -28.1% -26.1% -28.9% -32.5% -36.6% -45.3% -54.6% -61.6% -69.8% -43.2% -38.5% -16.2% -19.3% -36.1% -38.1% -49.2% -59.0% -74.6% -144.6% -200.7% -326.1% -558.6% -2,003.2% -220.3% -437.3% -135.3% -161.2% -222.9% -381.0% -352.3% -6,330.7% – – –
-44.6% -45.5% -47.9% -55.7% -67.0% -61.6% -24.9% -22.8% -25.0% -27.5% -32.2% -38.7% -45.1% -35.5% -34.5% -22.9% -20.2% -10.6% -12.7% -23.2% -23.9% -29.8% -34.0% -38.3% -41.9% -45.8% -52.0% -55.0% -51.3% -40.7% -46.9% -36.2% -36.3% -37.9% -41.9% -40.8% -48.7% -37.6% -47.0% -46.4%
Balance Sheet & Debt
-142 -161 -160 -91 -60 -100 -227 -111 -83 – -241 -124 -115 -426 -291 -328 -190 -705 -374 -281 -187 -297 -143 -148 -380 -121 -75 -91 -61 -201 -99 -469 -140 -163 -117 -154 -135 -353 -103 -49
88.5% 87.7% 89.5% 86.3% 84.0% 78.1% 88.5% 87.3% 86.6% 84.6% 88.0% 85.5% 82.6% 57.6% 49.4% 52.9% 52.5% 65.6% 66.0% 64.3% 62.9% 60.6% 57.5% 51.3% 29.0% 22.8% 15.9% 9.8% 2.6% 18.5% 10.7% 26.7% 22.5% 17.0% 11.0% 11.6% 0.8% -5.2% -18.2% -23.0%
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.4 0.0 0.1 0.0 0.0 0.0 0.1 0.1 8.5 – – –
Per Share
-5.81 -6.03 -6.25 -6.55 -6.87 -7.00 -4.15 -3.68 -3.81 -3.90 -6.10 -6.45 -6.88 -6.97 -7.33 -4.91 -4.22 -2.89 -3.04 -5.20 -5.24 -6.62 -6.76 -7.24 -9.68 -10.08 -10.22 -10.17 -8.86 -7.48 -7.28 -6.76 -5.85 -5.95 -5.71 -5.41 -5.81 -5.76 -6.06 -5.75
0.00 0.00 0.00 0.00 0.00 0.06 0.27 0.52 0.75 1.02 1.11 1.22 1.46 1.79 2.10 2.61 3.54 4.19 4.98 5.32 5.30 5.12 4.78 4.78 4.90 5.18 5.46 5.68 5.72 5.35 5.25 5.56 5.47 5.86 6.13 6.20 6.32 6.73 6.65 7.04
11.53 11.62 11.67 10.14 8.61 8.89 14.75 14.13 13.17 12.01 16.66 14.25 12.60 11.31 10.50 11.38 10.98 17.85 15.72 14.38 13.76 13.45 11.46 9.70 6.69 5.02 3.13 1.82 0.44 3.40 1.66 4.99 3.63 2.67 1.50 1.54 0.09 -0.80 -2.35 -2.86
-4.18 -4.20 -4.46 -4.51 -5.23 -5.95 -5.81 -6.29 -6.37 -5.81 -5.70 -5.57 -5.96 -6.40 -6.56 -3.32 -2.93 -2.72 -3.62 -6.08 -6.24 -6.01 -5.98 -6.27 -6.85 -7.51 -7.51 -7.80 -7.72 -6.43 -6.45 -5.69 -4.60 -4.54 -4.29 -4.34 -4.52 -4.72 -4.84 -4.80

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?